Fully biologically active when compared to standard. The biological activity is determined by its inhibitory effect of IL-8 production using human peripheral blood mononuclear cells. About 90 % of inibition was seen using a concentration of 1.0 μg for both 4-1BB Ligand and 4-1BB Receptor.

4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant is expressed in E. coli. The accession number is Q07011.

Human

E. coli

TNFRSF9,T-cell antigen ILA,CD137 antigen,4-1BB

Glu18-Ser184

> 97% as determined by SDS-PAGE; > 97% as determined by HPLC

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml.

Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

4-1BB(CD137) is a member of the tumor necrosis factor (TNF) receptor family. Mature human 4-1BB consists of a 163 amino acid extracellular domain (ECD) with four TNFR cysteine‑rich repeats, a 27 aa transmembrane segment, and a 42 aa cytoplasmic domain; 4-1BB (CD137) is expressed as a disulfide-linked homodimer on various populations of activated T cell including CD4 + , CD8 + , memory CD8 + , NKT, and regulatory T cells as well as on myeloid and mast cell progenitors, dendritic cells, mast cells, and bacterially infected osteoblasts. It binds with high affinity to the transmembrane 4-1BB Ligand/TNFSF9 which is expressed on antigen presenting cells and myeloid progenitor cells. This interaction co-stimulates the proliferation, activation, and/or survival of the 4-1BB expressing cell. It can also enhance the activation-induced cell death of repetitively stimulated T cells.